Postmarketing reporting patterns of Candida-related events associated with bimekizumab and selective IL-17A inhibitors in psoriasis: a FAERS and JADER pharmacovigilance study. (PubMed, Front Pharmacol) - Oct 8, 2026 - "The results support phenotype-focused pharmacovigilance follow-up and clinical awareness without ranking drug safety. These findings characterize spontaneous reporting patterns and should not be interpreted as estimates of incidence or comparative clinical risk."
Adverse events • Journal • P4 data • Atopic Dermatitis • Candidiasis • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Psoriasis • IL17A
|
|
Guihao Hou; Hao Zhong; Yige Yu; Yingyu Yu; Yongjian Liu
|